Stocks-RVNC-Revance Therapeutics Inc

RVNC Revance Therapeutics Inc

5.92 0 (0%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: Revance Therapeutics Inc's revenues increased by 70.40% and amounted to 132.57M. Net income decreased by 26.70% to -356.42M. Net assets decreased by 81.60% to 12.60M and EPS decreased from -4.17 to -4.90.
RVNC's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
48.57%
Net Profit Margin
-10,268.46%
Operating Margin
-113.11%
Return On Investment
-67.00%